ArticlePediatric nephrology (Berlin, Germany)2003
The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Efficacy and safety of levamisole in childhood nephrotic syndrome: A meta-analysis.Indian journal of pharmacologyPooled it
- Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Adrenocortical suppression increases the risk of relapse in nephrotic syndrome.Archives of disease in childhood · 2007Trial
- Long-term results of two unconventional agents in steroid-dependent nephrotic children.Pediatric nephrology (Berlin, Germany) · 2005Trial
- CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.BioMed research international · 2021Review
- Article
- Safety and Efficacy of Combination ACTHar Gel and Tacrolimus in Treatment-Resistant Focal Segmental Glomerulosclerosis and Membranous Glomerulopathy.Kidney international reports · 2017Article
- Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016Observational
- Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.British journal of clinical pharmacology · 2015Article
- Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome.International urology and nephrology · 2013Article
- Clinical course and outcome of children with steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Article
- Management patterns of childhood-onset nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2009Article
- Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2008Article
- Treatment of steroid sensitive nephrotic syndrome.Indian journal of pediatrics · 2005Review
- Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?Pediatric nephrology (Berlin, Germany) · 2005Review
- Long-term effects of levamisole treatment in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood nephrotic syndrome (NS) is frequently characterized by a relapsing course. There is no uniform agreement about the precise stage at which a steroid-sparing agent should be introduced to control the disease. In order to evaluate the treatment strategies and outcome of steroid-sensitive NS over the last 2 decades, a retrospective notes review was undertaken in a cohort of children treated at Great Ormond Street Children's Hospital between 1980 and 2000. From a population of 863 children with NS referred, 509 had frequently relapsing or steroid-dependent disease and 261 children received at least one steroid-sparing agent. Cyclophosphamide was the first choice in 178 patients and in 114 no further steroid-sparing agent was needed. Levamisole was prescribed as the first steroid-sparing agent for 65 children and disease control was achieved in 30%. Cyclosporin A was prescribed in 61 children and sustained remission was induced in 69%. It is concluded that cyclophosphamide is a potent agent in inducing sustained remission in steroid-sensitive NS. Levamisole and cyclosporin A have emerged as attractive steroid-sparing agents. Complications and major side effects of treatment are infrequent but occasionally fatal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.